Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (369)	8/11/2000 11:35:35 PM
From: Biomaven	Read Replies (1) \| Respond to of 496

Analyst Matt Geller of CIBC World Markets is impressed by Guilford's neurological compounds. ''They have the potential to revolutionize the treatment of neurological disorders,'' says Geller, who rates the stock a ''strong buy.'' So what explains this then? NEW YORK, Aug 11 (Reuters) - CIBC World Markets said on Friday that it is cutting its rating on Guilford Pharmaceuticals Inc. (NasdaqNM:GLFD - news) to a hold from a strong buy. On Monday, it will start Phase II clinical trials on a drug to treat Parkinson's disease in conjunction with drug maker Amgen Inc. (NasdaqNM:AMGN - news), Guilford said. I wonder what would he have done if AMGN had dropped the compound altogether? Raised GLFD to a "screaming buy"? Peter